Search for: "Watson et al v. United States Drug Enforcement Agency et al"
Results 1 - 2
of 2
Sorted by Relevance
|
Sort by Date
29 Aug 2022, 9:05 pm
The Executive Order endorsed this approach, noting that “this order reaffirms that the United States retains the authority to challenge transactions whose previous consummation was in violation of the [antitrust laws]. [read post]
15 Mar 2008, 7:00 am
India: Gene silencing: (Spicy IP), India: US Patent reform implications for Indian Pharma: (Spicy IP), India: Generic pharmaceutical industry in the spotlight: (International Law Office), India: Supreme Court refuses to stay a Gujarat High Court decision restraining Ranbaxy from airing its controversial ads directed against Paras Pharma's 'Moov' brand: (Spicy IP),India: Patents on ARV drugs could increase costs: (Generic Pharmaceuticals & IP),US: Survey shows most… [read post]
